Oxford BioMedica (OXBDF) Stock Price, News & Analysis

Company Overview

Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.

Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services. Oxford BioMedica has particular expertise in lentiviral vectors and also supports other vector platforms, including adeno-associated virus (AAV), for applications such as gene-modified cell therapies and in vivo gene therapies.

Founded in 1995 and headquartered in Oxford, England, the company has expanded its operations through facilities and businesses in the United Kingdom, Europe, and the United States. Oxford BioMedica also has a history of developing its own gene-therapy candidates, although its primary strategic focus is providing specialized development and manufacturing services to biopharmaceutical partners. The company is led by Chief Executive Officer Frank Mathias.

Key Stats

• Today's Range: $6.65 to $6.65
• 50-Day Range: $5.83 to $8.65
• 52-Week Range: $5.80 to $12.61
• Volume: 2,500 shs
• Average Volume: 1,509 shs
• Market Capitalization: $704.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Oxford BioMedica Stock Analysis - MarketRank™

Oxford BioMedica scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Oxford BioMedica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Oxford BioMedica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oxford BioMedica are expected to grow in the coming year, from ($0.17) to $0.13 per share.

Price to Book Value per Share Ratio

Oxford BioMedica has a P/B Ratio of 10.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.17% of the float of Oxford BioMedica has been sold short.

Short Interest Ratio / Days to Cover

Oxford BioMedica has a short interest ratio ("days to cover") of 43.77, which indicates bearish sentiment.

Change versus previous month

Short interest in Oxford BioMedica has recently increased by 56.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oxford BioMedica does not currently pay a dividend.

Dividend Growth

Oxford BioMedica does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Oxford BioMedica has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Oxford BioMedica this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oxford BioMedica insiders have not sold or bought any company stock.

Percentage Held by Institutions

Oxford BioMedica has minimal institutional ownership at this time.

Company Calendar

• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:OXBDF
• Previous Symbol: NASDAQ:OXBDF
• CIK: N/A
• Web: www.oxfordbiomedica.co.uk
• Phone: 44-18-6578-3000
• Fax: N/A
• Employees: 891
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $164.59 million
• Price / Sales: 4.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 10.73

Miscellaneous

• Outstanding Shares: 105,960,000
• Free Float: N/A
• Market Cap: $704.63 million
• Optionable: Not Optionable
• Beta: 1.20